Results from our study: NRAS andKRAS2 mutations in cases of MGUS, MM, P-PCL, and HMCL
Status . | NRAS mutations (%) . | KRAS2 mutations (%) . |
---|---|---|
MGUS | 1/9‡ | 0/9 |
MM, P-PCL at diagnosis | 10/40 (25)2-153 | 15/43 (35) |
Relapse | ||
Medullary* | 4/62-155 | 0/6 |
Extramedullary† | 0/5 | 5/5 |
HMCL | 4/152-154 | 4/15 |
Status . | NRAS mutations (%) . | KRAS2 mutations (%) . |
---|---|---|
MGUS | 1/9‡ | 0/9 |
MM, P-PCL at diagnosis | 10/40 (25)2-153 | 15/43 (35) |
Relapse | ||
Medullary* | 4/62-155 | 0/6 |
Extramedullary† | 0/5 | 5/5 |
HMCL | 4/152-154 | 4/15 |